Senior Manager(m/f/d), Market Access, TMTT, EMEACLA region
Edwards Lifesciences S.A.S [France]
Le poste en détail
Location
France, Italy, Spain, UK (remote or hybrid, country‑based)
Region: EMEACLA (Europe, Middle East, Africa, Canada, Latin America)
Team
This role is part of the Public Affairs team EMEACLA, reporting to the Sr Director Public Affairs, Business Partner TMTT ( Transcatheter Mitral & Tricuspid Therapies) Business Unit.
Works in close matrix with: Global Health Economics and Reimbursement, Clinical Affairs, Medical Affairs, Regulatory, and Business Unit teams
Role Purpose
The Senior Manager, Market Access TMTT EMEACLA is responsible for developing and executing regional and country‑level market access strategies in collaboration with the PA country head to secure timely, sustainable patient access and appropriate funding for Edwards Lifesciences’ innovative mitral and tricuspid transcatheter therapies.
This role operates at the intersection of health policy, reimbursement, and evidence generation, translating evidence and value strategies into actionable access pathways across diverse healthcare systems. The position plays a critical role in supporting innovation funding and accelerating patient access for breakthrough implantable devices addressing major unmet needs in structural heart disease.
How you’ll make an impact:
Contribute to the definition and execution of the EMEACLA Market Access strategy for TMTT, aligned with business priorities. Assess access and reimbursement issues that matter to the business to identify fast access pathways and optimal reimbursement.
Lead or support country‑level market access strategies, including Health Technology Assessment (HTA) submissions, Reimbursement and funding negotiations, Procedure coding, DRG creation or optimization, Innovation and early access mechanisms
Engage with national and regional decision‑makers, payers, and HTA bodies to define optimal access pathways for TMTT portfolio.
Actively contribute to EU HTA Regulation readiness for the TMTT Portfolio, including potential Joint Clinical Assessments (JCA) or Joint Scientific Consultations (JSC).
Translate EU‑level assessments into clear country‑level implications and action plans.
Partner with the Global and Regional Business Unit teams to align evidence generation plans with EMEACLA payer and HTA expectations.
Support development and localization of value dossiers, economic models, and evidence summaries.
Provide market access input into clinical development plans, including endpoint relevance and post‑market evidence needs.
Ensure market access considerations are integrated early into product strategy, launch planning, and lifecycle management.
Provide subject‑matter expertise and guidance on complex access topics.
What you’ll need:
Master’s degree or PhD in health economics, public health, biomedical sciences, Business, Political Sciences or a related field preferred.
8+ years of experience in Market Access, HEOR, Reimbursement, or related functions, ideally within medical devices or pharmaceuticals.
Proven experience with HTA processes and payer engagement in Europe (in particular in France, UK, Germany) for innovative healthcare technologies.
Regional or multi‑country experience within EMEA / EMEACLA strongly preferred.
Perfect command of English and French, with excellent written communication skills, is required
What else we look for:
Strong understanding of Market access and reimbursement pathways, Health Technology Assessment for medical devices, Evidence‑based value communication
Track record of engagement of experts and health authorities
Demonstrated ability to operate effectively in a matrix organization, influence without direct authority, manage multiple priorities across countries and stakeholders
Additional European languages are a strong asset
High ethical standards, professionalism, and stakeholder credibility.
Self-motivated, result oriented, problem solver with strong ownership and leadership skills.
Proven successful project management skills
What This Role Offers:
A strategic role in shaping access pathways for first‑in‑class mitral and tricuspid therapies, a direct involvement in EU and national HTA and reimbursement decision‑making, a high visibility within a cross‑functional, international environment, an opportunity to contribute meaningfully to improving outcomes for patients with severe structural heart disease.
About Edwards Lifesciences:
Edwards Lifesciences is the leading global structural heart innovation company dedicated exclusively to structural heart disease (SHD), a progressive, life-threatening condition affecting the heart’s valves, walls, chambers, and muscles. With over 65 years of pioneering innovation, the company is driven by a singular purpose: transforming SHD care to improve patient lives through breakthrough technologies, world-class evidence, and strong partnerships with clinicians and healthcare stakeholders. Headquartered in Irvine California, Edwards is a global company with 16,000 employees including 2,850 in the EMEA, Canada and Latin-America region (EMEACLA).
The Edwards Lifesciences Transcatheter Mitral and Tricuspid Therapies (TMTT) business unit is at the forefront of one of the most exciting frontiers in cardiovascular innovation. With a first‑in‑class portfolio spanning both repair and replacement therapies, TMTT is transforming care for patients with severe mitral and tricuspid valve disease and shaping the future of structural heart therapies worldwide.
What is it like to work at Edwards Lifesciences in France?
As a global leader in patient-focused medical innovations, we offer rewarding opportunities and exciting challenges in a truly international, dynamic and friendly work environment.
We are committed to fostering a diverse and inclusive work environment where all employees can grow, personally and professionally. To achieve this, we offer on-the-job development, training opportunities and the support and guidance provided by dedicated employee groups (the Edwards Network of Women, Edwards Foundation charity team, sustainability activities, and others).
Edwards Lifesciences in France also offers the following benefits:
Competitive Compensation and Benefits package
Flexible working hours, remote working
Profit sharing
Risk Life Insurance
Comprehensive Medical plan (including online access to healthcare)
Service Awards
Works Council social and cultural activities
Enhanced Leave Benefits
Employee Stock Purchase Program
Employee Assistance Program
Comprehensive Wellness Program including onsite gym, Yoga, Pilates or SM System classes, massages, fresh fruit in the office, healthy lifestyle workshops, educational events, charity activities and much more.
Benefits are regulated by an internal policy which contains the full details regarding the entitlement and conditions for the benefits. Benefits policy and components may vary by location.
